Vesiculab’s Post

We are excited to announce that Malavika Ghosh, Senior Vice President, Preclinical Efficacy Testing, Aragen Bioscience, will be presenting a poster on "Phenotypic Characterization of Repetitive Bleomycin-Induced Chronic Pulmonary Fibrosis Model in Mice" at the 8th Annual IPF Summit from August 20-22, 2024 in Boston, MA. Idiopathic pulmonary fibrosis (IPF) is a severe and progressive lung disease. Research done by our experts, established a repetitive bleomycin model in mice that accurately reflects the persistent and progressive nature of human IPF. Through three bi-weekly bleomycin instillations, our model demonstrates significant fibrosis progression, impaired lung function, and consistent gene expression and cytokine profiles, making it a valuable tool for studying progressive fibrosis. Visit us at Booth No. 2 to learn more about this innovative model and its implications for IPF research. Click here https://lnkd.in/gFff_EP6 to block a meeting slot now with our experts. See you in Boston! Danielle Liu #summits2024 #posterpresentation #boston #pulmonary #fibrosis #preclinical #lungdiseases #cdmo #cro #endtoendsolutions

📣To commemorate Global #FattyLiverDay, I’m delighted to share our latest PhysioMimix® OOC Application Note: Developing a translational biomarker panel for use in pre-clinical advanced in vitro studies of Non-alcoholic steatohepatitis (NASH) with you. It explores: · The recapitulation of an advanced NASH phenotype, characterized by fibrosis and the quantification of biomarkers. · The ability of four clinically-tested NASH drugs to resolve the disease phenotype · How the PhysioMimix NASH assay aids data translatability between the lab and clinic. NASH is now also known as MASH (Metabolic dysfunction-associated steatohepatitis) 👉Download your copy of the App Note here: https://bit.ly/4b6P8Ia #ActNowScreenToday #MASLD #NAFLD #NASH #MASH

The Topic # 13 in the CADD series is ready! This time, we’re focusing on Protein-Protein Interactions (PPIs) and how AlphaFold2 is transforming the way we approach these interactions in drug discovery. These slides will cover the challenges of targeting PPIs and explain how AlphaFold2’s highly accurate predictions are enabling new opportunities in drug design. You’ll also find examples of real-world applications in diseases like cancer, neurodegeneration, and infectious diseases. #CADD #ProteinProteinInteractions #DrugDiscovery #PPIs #PharmaceuticalResearch #MedicinalChemistry #Biotechnology #CancerTherapy #NeurodegenerativeDiseases #InfectiousDiseases

Unlock the full potential of precision medicine with #Immunopeptidomics! 🧬 This cutting-edge field analyzes peptides on MHC-I or II proteins, like HLA, to identify tumor antigens. 🌟 Technologies such as immunoaffinity purification & HPLC-MS/MS make it a game-changer in cancer therapy. Learn more: https://lnkd.in/dRUJ_3gj #CancerResearch #PrecisionMedicine #Biotechnology #HealthTech

Hello from San Antonio! Meet the team at #WRIB to discuss how CyTOF® technology can provide superior resolution for intracellular targets, enabling accurate analysis and precise detection of immune cell populations with distinct functional signatures. Available in a standardized assay format on the automated CyTOF XT™, the technology can accelerate biomarker discovery, single cell analysis and immune profiling applications to facilitate therapeutic design and advance disease monitoring. Learn more: https://lnkd.in/ggNn5vwM #bioanalysis #quantitativeanalysis #cellbiology

https://lnkd.in/gaHvd4PV 🧬 Dr. Diego Fernández Lázaro Ph.D. et al's review explores apoptosis, necroptosis, and autophagy mechanisms, highlighting caspase-dependent and independent pathways. 📊 Key proteins like caspases, Bcl-2, AIF, and Endonuclease G are examined. 💡 Understanding these pathways reveals biomarkers and therapeutic targets for various diseases. #CellBiology #Apoptosis #Proteomics

Excited to share insights from Wing Cheng’s interview about the groundbreaking potential of Anti-sense Oligonucleotide (#ASO) therapeutics! Key Takeaways: - Innovative treatments: ASOs are emerging as promising solutions for genetic disorders and targeted cancer therapies. - Growing acceptance: With 19 ASOs approved by 2023, clinical trials are catching up to the popularity of antibody therapies. - Overcoming challenges: Drug development remains complex, particularly in avoiding immune system triggers like Complement activation. - Advancing research: Current non-clinical models fall short in studying human genetic diseases. A human whole blood assay could revolutionize this field. - Regulatory collaboration: With no official guidelines yet, a proactive dialogue with regulatory agencies is essential to demonstrate safety before IND filing. Join Immuneed in exploring the future of #ASO therapeutics and its transformative potential in medicine!

🌟Exciting times in the field of ASO Therapy!🌟   I am thrilled to share my views of the incredible potential of antisense oligonucleotide(ASO) therapy. This cutting-edge approach leverages short DNA or RNA molecules to target and modify genetic sequences, offering promising solutions for a range of diseases, from rare genetic disorders to more common conditions like cancer and viral infections. 🤩 If you're interested in learning more, collaborating, or discussing the latest developments in this dynamic field, let's connect! ➰🤝   #Immuneed #IDFlow #NucleotideTherapy #PrecisionMedicine #HealthcareTransformation

🔬 Exploring Acute Tubular Injury through Plasma Proteomics 🚀 The kidney tubules are powerhouses of metabolic energy. In the battle against kidney diseases, acute tubular injury (ATI) plays a pivotal role in potentially accelerating kidney failure. Our recent study leverages the cutting-edge SomaScan proteomics platform on 434 patients with biopsy-confirmed kidney disease. We uncovered 156 plasma biomarkers intricately linked with ATI severity, with osteopontin, macrophage mannose receptor 1, and tenascin C showing the strongest associations. Through advanced techniques like regional transcriptomics, single-cell RNA sequencing, and pathway analysis, we delved deep into biomarker protein and gene expression. The findings aren't just data points—they reveal crucial insights into immune regulation and organelle stress responses within ATI pathogenesis. This research could pave the way for non-invasive biomarkers for early ATI detection and potential new treatments. Excited to see the strides we make towards combating kidney diseases! 🌟🔍🧬 Read Research 👉🏻 https://lnkd.in/d3EyYX4i #research #pubmed

"Hasta la Vista" to binding in trans 🤔 | #VISTA & #Ligands interact in cis 😮 | Major VISTA-based #Immunotherapy Implications from Karina Smorodinsky et al for #Cancer & #AutoImmuneDiseases 👍 | Breaking Open Access Study | VISTA, an essential immune checkpoint regulatory protein, regulates peripheral T-cell quiescence and tolerance. Despite its potential as a target for anti-tumor and autoimmune disease therapies, uncertainty regarding VISTA’s binding mode and membrane orientation has hindered these developments. Contrary to the prevailing paradigm, we found using cell aggregation assays that VISTA cannot interact with its ligands in trans (between cells). Here*, using MST and flow cytometry, the authors showed that soluble VISTA binds to its ligands, suggesting that VISTA’s membrane orientation restricts trans interactions. In contrast, split luciferase complementation assays showed that VISTA interacts with its ligands in cis. They propose that a disulfide bond bends VISTA’s Ig domain towards the membrane in an orientation that prevents trans while enabling cis interactions. Co-expression data analysis from the cancer genome atlas showed a strong correlation between VISTA and its ligand, PSGL-1, consistent with the in-vitro cis interaction data. These findings reveal VISTA’s binding mechanism and suggest an intrinsic inhibition signaling pathway independent of additional cells. Importantly, their experimental framework provides a platform for identifying novel VISTA-targeted therapeutics. *https://lnkd.in/dXMduvG7 Celentyx Ltd #immunooncology #drugdiscovery www.celentyx.com Professor Nicholas Barnes PhD, FBPhS Omar Qureshi Catherine Brady FIGURE | VISTA and its related ligands | Taken from Behzad Baradaran, Seyed Amir Jalali & Co. | https://lnkd.in/dQnFEwMP |